J. Dufour
Hepatology · 2010–2021
A researcher in the Science corpus: 8 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 150 citations into it
Whom J. Dufour trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from J. Dufour's perspective
Ordered by how strongly the researchers J. Dufour trusts endorse each paper. Same corpus, a different order for every researcher.
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
- Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
- INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
- The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
- Noninvasive assessment of liver fibrosis (Hepatology)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
- Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
Their papers
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
- A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) — 3,051 citations
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) — 799 citations
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) — 596 citations
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) — 653 citations
- Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. (2010) — 1,230 citations